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Introduction
Homeostasis is an essential aspect of the mammalian
immune system [1,2]. The majority of lymphocytes that
expand and proliferate in response to antigens in vivo has
to subsequently die to maintain a constant number of
these cells between immune responses. During the initial
expansion phase of an immune response, T cells and B
cells are induced to divide by antigens, growth factors and
cytokines. These agents trigger cellular signals that
sustain lymphocyte growth and survival. During the eclipse
phase of an immune response, however, apoptosis (pro-
grammed cell death [PCD]) must occur to reduce the
number of accumulated cells and to restore homeostasis.
These survival and apoptotic signals are highly regulated
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Chapter summary
Signal transduction induced by tumor necrosis factor (TNF) family members and their receptors has
been an intensive area of research for several years. The major impact of these studies has been the
delineation of apoptotic and cell survival signaling pathways. These discoveries, coupled with major
advances in the study of mammalian apoptotic machinery, constitute a promising blueprint of the
molecular network governing the fate of all living cells. In this review, we concentrate on the fate of
cells in the immune system, where regulation of cell death and cell survival is a frequent and important
exercise. A small imbalance in favor of either fate can result in disastrous pathological outcomes, such
as cancer, autoimmunity or immune deficiency. It is an insurmountable task to discuss all molecules
reported in the literature that are implicated in lymphocyte death or survival. We have therefore focused
on discoveries made by mouse gene targeting, as these studies provide the most physiologically
relevant information on each molecule. We begin with a description of signaling channels initiated by
TNF receptor type 1 engagement, which can lead to either cell survival or to cell death. The point of
bifurcation of this pathway and the decision-making molecules FADD, TRAF2 and RIP are discussed.
We then follow apoptotic and survival pathways from upstream to downstream, describing many
important players involved in signal transduction. Molecules important for NF-κB and JNK/stress-
activated protein kinase activation such as IKKβ, NEMO, MAP3K and TRAF6 are discussed, as is the
impact of BAFF and its receptors on B-cell survival. Mouse mutants that have helped to define the
mammalian apoptosis execution machinery, including animals lacking Apaf-1, caspase-3 and
caspase-9, are also described. We conclude with a brief analysis of the potential therapeutic options
arising from this body of work.
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[3,4], and the understanding of the processes mediating
these cellular decisions should aid in the design of rational
therapeutics for autoimmune diseases, inflammation and
infections.
For the immune system, many apoptotic signals and sur-
vival signals are mediated via receptors present on the
surfaces of lymphocytes and other hemopoietic cells. The
most prominent of these receptors belong to a group of
structurally related signaling proteins called the TNF
receptor (TNFR) superfamily [5–7]. Over the past decade,
many TNFRs and their ligands have been molecularly
cloned and characterized.
Even more exciting is the identification of the myriad of
downstream effector proteins involved in coordinating and
controlling various signaling cascades. Both apoptotic
signals and survival signals in lymphocytes are primarily
mediated by various members of the TNFR superfamily.
Intriguingly, in some cases, signals associated with PCD or
survival can be transmitted through the same receptor in
response to the same ligand. Understanding how such
signal transduction is executed is a key goal for the many
laboratories studying immune and inflammatory responses.
In the present review, we shall concentrate on information
gained from studies of gene-targeted mutant mice defi-
cient in the expression of proteins involved in apoptotic
and survival signaling pathways in lymphocytes. We shall
focus particularly on signal mediators and effectors that
act in the TNFR pathways and on the common apoptosis
execution machinery. For a more in-depth survey of work
in this area, please refer to other recent comprehensive
reviews [2–11].
TNFR superfamily
The most important members of the TNFR superfamily
involved in lymphocyte signal transduction are TNF recep-
tor-associated factor type 1 (TNFR1), TNF receptor-asso-
ciated factor type 2 (TNFR2) and Fas (CD95). TNFR1 and
TNFR2, which both bind to the cytokine TNF, were the
first members of the TNFR family to be identified.
Studies of gene-targeted mice lacking expression of
TNFR1 demonstrated that this receptor is involved in sig-
naling leading to inflammation and cell survival [12]. Para-
doxically, however, PCD was also found to be impaired in
TNFR1–/– mutants [13]. In response to a single ligand
(TNF), TNFR1 thus mediates not only survival and inflam-
matory signaling, but also apoptotic signaling. In contrast,
in response to TNF binding, TNFR2 transduces signals
principally for survival and inflammation [8]. The Fas
(CD95) receptor, which was originally discovered as the
product of the mutated gene in MRL/lpr mice [14], medi-
ates mainly signals for apoptosis in response to the
binding of its ligand FasL. Mice deficient for Fas or FasL
show massive lymphoadenopathy and disruption of lym-
phocyte homeostasis due to a lack of PCD.
How is the signaling initiated by engagement of TNFR
superfamily members transduced within the cell? In
response to ligand binding, various proteins are recruited
to specific domains in the cytoplasmic tails of the recep-
tors. It is these downstream effectors, which vary in struc-
ture and function, that determine signaling outcomes.
Some effectors are enzymes, such as kinases, phos-
phatases and proteases, some are adaptor proteins that
serve to recruit still more signaling intermediaries, and
some are regulatory proteins. Understanding the nature
and functions of these downstream effectors will allow us
to explain how particular cellular outcomes result from sig-
naling through a limited number of receptors.
TNFR superfamily members are categorized into two
classes based on the effectors recruited to their cytoplas-
mic domains. In the first class, which includes TNFR1,
Fas, death receptor (DR)3, DR4, DR5 and DR6, the cyto-
plasmic tail contains a ‘death domain’ (DD) [6,15]. The
DDs may vary slightly in sequence between receptors but
all are highly homologous and provide the capacity for
protein–protein interaction. The DD in a receptor tail
recruits intracellular adaptor proteins that also contain a
DD. For example, TNFR1 contains a DD that binds to the
TNF receptor-associated death domain protein (TRADD),
and Fas contains a DD that binds to both Fas-associated
death domain protein (FADD) and receptor-interacting
protein (RIP) [5,9] (Fig. 1).
The second class of TNFR superfamily receptors includes
TNFR2, CD30, CD40, lymphotoxin receptor, the osteopro-
tegerin ligand (OPGL) receptor activator of NF-κB (RANK),
and B-lymphocyte activating factor (BAFF) receptors
[6,16]. The cytoplasmic tails of these receptors do not
contain DDs. Instead, they have sequences allowing them
to associate with a different set of intracellular adaptors
called TNF receptor-associated factors (TRAFs) [17,18].
Although six TRAF proteins (TRAF1–TRAF6) have been
identified to date, only five (TRAF1, TRAF2, TRAF3, TRAF5
and TRAF6) actually bind to the cytoplasmic tails of the
second class of TNFR superfamily receptors.
Other groups and ourselves have generated gene-
targeted ‘knockout mice’ for several signaling proteins
downstream of these receptors, and have been able to
gain insights into their functions and regulation from exam-
ining the phenotypes of these animals and their cells. In
the present review, we discuss the receptor-proximal sig-
naling adaptors and their key functions in deciding
whether a cell will survive or will undergo apoptosis. We
also examine the successive molecular events that make
up the initial phase of the cascade of apoptosis, and its
terminal execution machinery.S245
FADD, TRAF2 and RIP
It is now well established that TNFR1 can mediate signals
for either apoptosis or cell survival. Which signaling path
is triggered following receptor aggregation appears to be
a function of the recruitment of the different adaptor pro-
teins appropriate for each path. Indeed, Hsu et al. showed
that when TRADD binds to TNFR1, TRADD can then
associate with either FADD or TRAF2 and with RIP [19]
(Fig. 1). This observation led to the hypothesis that recruit-
ment of FADD to the TNFR1 complex would lead to PCD,
while recruitment of TRAF2 and RIP would signal for sur-
vival. We tested this hypothesis by generating gene-
targeted mutant mice deficient for expression of either
FADD or TRAF2.
FADD-deficient mice do not survive beyond day 11.5 of
embryogenesis [20,21], indicating that FADD is essential
for embryonic development. In situ hybridization studies
confirmed that FADD is expressed widely during embryo-
genesis, consistent with its role in fundamental develop-
mental processes. Most FADD–/– embryos have thin ven-
tricular myocardium, poorly developed inner trabeculation,
and abdominal hemorrhage.
The precise function of FADD in embryonic development
is not clearly understood at this time. Using cells derived
from FADD–/– embryos, however, we have demonstrated
the importance of FADD in apoptotic signaling initiated by
TNFR superfamily receptors. Following engagement of
Fas, TNFR1 or DR3, apoptosis was dramatically reduced
in FADD–/– cells compared with in controls. However,
levels of PCD in response to viral oncogene overexpres-
sion or chemotherapeutic drug administration were normal
in FADD–/– cells [20], indicating that not all agents induc-
ing apoptosis transduce their signals through FADD. Inter-
estingly, FADD-deficient T cells, in addition to being
resistant to Fas-induced apoptosis, showed a defect in
activation-induced proliferation [21].
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Figure 1
Intracellular signaling pathways downstream of tumor necrosis factor (TNF) receptor superfamily receptors. The Fas, tumor necrosis factor receptor
type 1 (TNFR1) and tumor necrosis factor receptor type 2 (TNFR2) receptors are shown extending through the cell membrane with their
extracellular domains projecting into the extracellular space. Various adaptor proteins and signal transducing molecules that convey signals initiated
by the binding of the ligands Fas ligand (FasL) to Fas and TNF to TNFR1 and TNFR2, respectively, are shown, as is the crosstalk between various
molecules and pathways. Functional domains within a protein are shown as colored blocks. Recruitment of one protein to another is indicated by
the juxtaposition of like-colored and like-shaped domain blocks. BID, beta interaction domain; cIAPs, cellular inhibitors of apoptosis; FADD, Fas-
associated death domain protein; IKK, IκB kinase; JNK, c-Jun N-terminal kinase; MAP3K, mitogen-activated protein 3 kinase; NEMO, NF-κB
essential modulator protein; RIP, receptor-interacting protein; T2K, TRAF2-associated kinase; TANK, TRAF family member associated NF-κB
activator; TRADD, TNF receptor-associated death domain protein; TRAF, TNF receptor-associated factor.S246
In contrast, TRAF2–/– cells showed increased levels of
PCD on stimulation by TNF [22], consistent with a
scenario in which cell survival depends on the recruitment
of TRAF2 to TNFR1. Surprisingly, however, TRAF2–/– cells
were still able to activate the transcription factor NF-κB
following engagement of TNFR1. The activation of NF-κB
had previously been thought to depend on signaling
through TRAF2, in that a dominant negative TRAF2
protein blocked TNF-mediated activation of NF-κB. Rather
than effects on NF-κB, we found that TNF-induced activa-
tion of the Jun kinase (JNK) pathway was greatly impaired
in the absence of TRAF2. Interestingly, cells deficient in
RIP, another adaptor protein associated with TRADD,
show a reduction in TNF-mediated NF-κB activation [23].
Taken together, these results indicate that cell survival sig-
naling mediated by TRAF2 does more than just activate
NF-κB. The JNK pathway and perhaps other proteins,
such as the cellular inhibitors of apoptosis, may also con-
tribute to TNF-induced cell survival [24].
Caspase-8 and c-FLICE (caspase-8) inhibitory protein
Caspase-8 is the key initiator caspase downstream of the
apoptosis pathway induced by TNFR1 and other death
receptors (Fig. 1). Caspase-8 interacts with FADD through
homologous death effector domains. Aggregation and close
proximity result in the activation of caspase-8 such that its
caspase domain is processed into two active subunits.
c-FLICE (caspase-8) inhibitory protein (c-FLIP), a cellular
homolog of viral FLICE (caspase-8) inhibitory protein, is
structurally similar to caspase-8 in that it possesses death
effector domains and a caspase-like domain. However, c-
FLIP lacks caspase enzymatic activity. It is thought that c-
FLIP recruited by FADD to the receptor complex in the
place of caspase-8 impedes the progression of apoptotic
signals. Caspase-8 and c-FLIP thus appear to play critical,
but opposite, roles in regulating DR signaling.
Mice lacking caspase-8 are phenotypically similar to FADD-
deficient mice [25]. Caspase-8–/– mice die at approximately
day 12.5 of embryogenesis with apparent hyperemia and
heart defects. Caspase-8–/– cells, like FADD–/– cells, are
specifically resistant to DR-induced apoptosis. Surprisingly,
c-FLIP–/– mice show a very similar embryonic phenotype to
FADD–/– mice and caspase-8–/– mice [26]. The ventricular
myocardium and trabeculae are poorly developed in day
10.5 of embryogenesis c-FLIP–/– embryos.
Like FADD-deficient embryos, embryos lacking c-FLIP do
not show signs of increased or decreased cell death, sug-
gesting that the developmental defects in these mutant
mice may be independent of apoptosis. In contrast, cells
lacking c-FLIP are highly sensitive to apoptotic stimuli that
trigger death receptors [26]. This result is consistent with
the predicted role of c-FLIP to counteract FADD and
caspase-8 in the regulation of DR-induced apoptosis.
Bid and Bim
Bid is a proapoptotic Bcl-2 family member that is
cleaved and activated by caspase-8 in response to DR
signaling. Bid then translocates to the mitochondria and
mediates the release of cytochrome c that leads to
apoptotic changes (Fig. 2). Bid-deficient mice are resis-
tant to the anti-Fas antibody-induced apoptosis of hepa-
tocytes that kills wild-type mice. However, a milder
defect of FasL-induced or TNF-induced apoptosis was
observed in Bid-deficient thymocytes and mouse embry-
onic fibroblasts (MEF) [27]. These results suggest that,
depending on tissue type, DR-induced apoptosis does
not necessarily have to go through Bid and the mito-
chondrial pathway.
Bim is another proapoptotic Bcl-2 family member that is
not involved in the DR pathway but is critical for thymocyte
negative selection. Bim-deficient thymocytes are refractory
to apoptosis induced by TCR stimulation, and autoreactive
thymocytes accumulate in TCR transgenic Bim–/– mice
[28]. Moreover, Bim-deficient lymphocytes accumulate in
peripheral blood and in the spleen, and these cells are
resistant to apoptotic stimuli such as cytokine deprivation
and microtubule perturbation [29].
Mitogen-activated protein 3 kinases
During the induction of cell survival by TNFR1 engage-
ment, a number of mitogen-activated protein 3 kinase
(MAP3K) family members has been shown to associate
with TRAF2 or RIP (Fig. 1). NF-κB inducing kinase (NIK)
was initially proposed to be the downstream target of
TRAF2 in mediating TNF-induced NF-κB activation
leading to survival [30]. However, NIK-deficient mice show
a specific defect in lymph node development and in lym-
photoxin-β-receptor signaling [31,32], and cells lacking
NIK respond normally to TNF in activating NF-κB.
Instead, the mitogen-activated protein extracellular signal
regulated kinase kinase (MEKK)-1 was implicated in this
NF-κB activation pathway [33]. In addition, MEKK-1 and
apoptosis signal-regulating kinase 1 (ASK-1) were
reported to mediate TRAF2-triggered JNK activation
[34–36]. From studies of knockout mice, however, it
seems that MEKK-1 is required for TNF-induced JNK acti-
vation only in embryonic stem cells and not in fibroblasts
or T cells [37–39]. Similarly, ASK-1 is not required for
early phase TNF-induced JNK activation, and ASK-1–/–
cells exhibit only a partial defect in sustained stress
kinase activation [40]. A new member of the MEKK family
(MEKK-3) has recently been found to associate with RIP,
meaning that it could potentially play a role in down-
stream survival signaling. Indeed, disruption of MEKK-3
severely impairs the activation of NF-κB induced by TNF,
and MEKK-3–/– cells are highly sensitive to TNF-induced
apoptosis [41].
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The Iκ κB kinase complex
NF-κB is a key transcription factor whose activation gener-
ally promotes cell survival. Mice lacking RelA (p65), a prin-
cipal subunit of NF-κB, die during embryogenesis due to
massive liver apoptosis [42]. NF-κB is normally held inac-
tive in the cytoplasm by its association with the inhibitor of
NF-κB protein, IκB. To activate NF-κB, IκB must be
removed via phosphorylation followed by ubiquitination
and proteasomal degradation. Phosphorylation of IκB is
mediated primarily by the IκB kinase (IKK) complex con-
taining the proteins IKKα, IKKβ and NF-κB essential mod-
ulator (NEMO) (also known as IKKγ) [10]. IKKα and IKKβ
are active kinases, while NEMO is a regulatory protein that
binds tightly to both kinases.
Deficiency for IKKβ is embryonic lethal, with the mice dis-
playing a liver apoptosis phenotype similar to that of the
RelA knockout [43–45]. In addition, the activation of
NF-κB by TNF or IL-1 is defective in IKKβ–/– cells. Recon-
stitution of lethally irradiated hosts with IKKβ-deficient fetal
liver cells revealed a defect in T-lymphocyte survival [46].
The absence of T cells in the IKKβ-deficient fetal liver
chimerae was due to the activity of circulating TNF, and
normal development of T cells was restored in mice
lacking both IKKβ and TNFR1.
NEMO-deficient mice also display a phenotype of fetal
liver apoptosis and embryonic lethality, consistent with
an essential role for NEMO in the central pathway medi-
ating NF-κB activation [47]. Like RelA–/– cells and
IKKβ–/– cells, NEMO–/– cells show an increased suscep-
tibility to TNF-induced apoptosis. NEMO is an X-linked
gene, and female NEMO+/– mice develop a self-limiting
inflammatory skin disorder characterized by hyperkerato-
sis and increased apoptosis. This phenotype is presum-
ably dependent on X-chromosome inactivation [48,49].
Importantly, these symptoms are reminiscent of inconti-
nentia pigmenti, an X-linked dominant hereditary disease
in humans. Indeed, genetic studies of incontinentia pig-
menti patients have revealed mutations in the NEMO
gene and defects in NF-κB activation in the majority of
cases [50].
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Figure 2
Intrinsic and extrinsic pathways of apoptosis. The extrinsic pathway is triggered by death receptor engagement, which initiates a signaling cascade
mediated by caspase-8 activation. Caspase-8 both feeds directly into caspase-3 activation and stimulates the release of cytochrome c by the
mitochondria. Caspase-3 activation leads to the degradation of cellular proteins necessary to maintain cell survival and integrity. The intrinsic
pathway occurs when various apoptotic stimuli trigger the release of cytochrome c from the mitochondria (independently of caspase-8 activation).
Cytochrome c interacts with Apaf-1 and caspase-9 to promote the activation of caspase-3. Various intermediary signaling molecules (many of
whose functions are not completely defined) and proteins inhibiting the apoptotic cascade are also shown. Apaf-1, apoptosis-activating factor 1;
Bak, bacille Calmette–Guérin; Bax, BCL-2-associated x protein; Bid, proapoptotic Bcl-2 family member; Bim, proapoptotic Bcl-2 family member;
DIABLO, direct IAP binding protein with low PI; FADD, Fas-associated death domain protein; IAP, inhibitors of apoptosis; Smac, second
mitochondria-derived activator of caspase; tBid, truncated beta interaction domain.S248
Interestingly, IKKα-deficient mice do not exhibit a fetal liver
defect like IKKβ–/– mice. Instead, IKKα–/– mice display
abnormal limb and skeletal patterns and display defective
epidermal differentiation [51,52]. The defect in skin forma-
tion seems to be independent of NF-κB activity and is due
instead to failed secretion of a keratinocyte differentiation-
inducing factor [53]. IKKα is not required for IKK or NF-κB
activation in response to inflammatory cytokines. Further
studies have revealed that IKKα is required for B-cell mat-
uration and secondary lymphoid organogenesis. Most
recently, it has been found that IKKα does play a role in
NF-κB activation by mediating the processing of the
NF-κB2 (p100) precursor protein [54,55].
TRAF2-associated kinase, glycogen synthase kinase 3β β
and atypical protein kinase C
NF-κB activation can occur via signaling pathways that are
independent of the IKK complex. TRAF2-associated
kinase (T2K) (also called TBK and NAK) associates with
TRAF2 through an intermediary protein, TRAF family
member associated NF-κB activator (TANK) [56–58].
TANK is a serine threonine kinase that is distantly related
to IKKα and IKKβ. TANK phosphorylates serine 36 on the
IκBα subunit of IκB, but this partial phosphorylation is not
sufficient to trigger degradation of IκB. T2K–/– cells show
normal IκB phosphorylation and degradation, normal
NF-κB translocation into the nucleus, and normal NF-κB
binding to target DNA sequences in response to TNF and
IL-1. However, NF-κB transactivation activity is affected in
cells lacking T2K [58]. This phenomenon is validated by
the phenotype of T2K–/– mice, which show liver apoptosis
and embryonic lethality similar to that in mice lacking RelA,
IKKβ or NEMO. Furthermore, elimination of TNFR1
rescues T2K-deficient mice from embryonic lethality, and
the double-knockout animals survive for extended periods
with no gross abnormalities [58].
The kinases glycogen synthase kinase (GSK3)α and
GSK3β act as inhibitory components of the Wnt signaling
pathway important for embryonic development. In frogs
and zebrafish, GSK3 is required for the definition of the
embryonic axes [59]. However, analysis of GSK3β-defi-
cient mice revealed a surprisingly specific and limited phe-
notype of fetal liver apoptosis similar to that in mice with
NF-κB activation defects [60]. GSK3β–/– MEF were highly
susceptible to TNF killing, much like wild-type fibroblasts
treated with TNF in the presence of the documented
GSK3 inhibitor lithium. Interestingly, TNF-induced IκB
phosphorylation and degradation were normal in GSK3β–/–
cells, but NF-κB activation was diminished due to reduced
DNA binding activity and due to severely impaired tran-
scriptional activation of a target reporter gene [60].
Another molecule implicated in TNF-induced NF-κB acti-
vation is atypical protein kinase C (ζPKC). ζPKC associ-
ates with RIP through the adapter protein p62 [61]. A lack
of ζPKC severely impairs cellular responses to TNF that
depend on the transcriptional activity of NF-κB [62].
However, IKK activation is normal in ζPKC-deficient MEF,
and NF-κB DNA binding is only mildly reduced in
response to TNF. Intriguingly, RelA phosphorylation is
defective in ζPKC–/– cells, suggesting that an alternative
pathway may exist to activate NF-κB. While ζPKC–/– cells
are hypersensitive to TNF-induced apoptosis, ζPKC–/–
mice do not exhibit fetal liver apoptosis or embryonic
lethality [62]. These mutant mice are viable but display a
reduced number of Peyer’s patches.
TNF receptor-associated factor 6
TRAF6 is emerging as one of the key players in survival
signaling. TRAF6 binds to the cytoplasmic tails of both the
B-cell costimulatory molecule CD40 and the inflammatory
IL-1 receptor [17]. In response to the binding of CD40
ligand and IL-1 to CD40 and IL-1 receptor, respectively,
TRAF6 mediates the activation of NF-κB and JNK/stress-
activated protein kinase. Study of TRAF6–/– cells con-
firmed the importance of TRAF6 in NF-κB activation in
response to CD40 or IL-1 signaling [63].
Interestingly, lipopolysaccharide signaling was also
impaired in TRAF6–/– cells, suggesting that TRAF6 may be
involved in signal transduction downstream of the Toll-like
receptors, particularly Toll-like receptor 4. A most unex-
pected finding was that TRAF6–/– mice suffered from
severe osteopetrosis, showing defects in tooth eruption
and bone remodeling due to impaired osteoclast function
[63]. Interestingly, mice lacking expression of OPGL [64],
the ligand for RANK, also exhibited osteopetrosis, strongly
suggesting that TRAF6 may act downstream of RANK.
OPGL–/– mice also show defects in T-cell and B-cell
homeostasis [64].
BAFF and its receptors
BAFF (also called BlyS, TALL-1 or zTNF4) is a new TNF
family member that has been implicated in promoting
B-cell survival [16]. Mice overexpressing BAFF display
mature B-cell hyperplasia and systemic lupus erythemato-
sus-like symptoms. Conversely, BAFF-deficient mice show
a complete loss of follicular and marginal-zone B lympho-
cytes [65]. Moreover, both T-cell-dependent and T-cell-
independent antibody responses are impaired in mice
lacking BAFF.
BAFF can bind to three receptors on the cell surface,
B-cell maturation antigen (BCMA), transmembrane activa-
tor and calcium modulator and cyclophilin ligand interac-
tor (TACI) and BAFF-R. Studies of knockout mice have
shown that these molecules are not directly equivalent in
function [66,67]. Mice lacking BCMA show normal B-cell
development and antibody responses [68], while TACI-
deficient mice are deficient only in T-cell-independent
antibody responses [69,70]. Paradoxically, mice lacking
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TACI show increased B-cell proliferation and accumula-
tion, suggesting an inhibitory role for TACI in B-cell home-
ostasis. Gene-targeted mice lacking BAFF-R have yet to
be reported, but the natural mouse mutant A/WySnJ has
a disruption of the intracellular domain of BAFF-R.
A/WySnJ mice display a phenotype that is similar to
BAFF–/– mice, although follicular and marginal-zone B
cells are not completely abolished [65]. In addition,
A/WySnJ mice are impaired only in T-cell-dependent anti-
body responses, unlike the more comprehensive defect
observed in BAFF-deficient mice. These results suggest
that, while BAFF-R may be the major receptor relaying
BAFF-mediated signals for B-cell survival, some redun-
dancy in function may be provided by the other two
receptors, particularly TACI.
Apoptosis execution machinery
In mammals, apoptosis depends on the actions of a family
of cysteine proteases called caspases. Two classes of
caspases exist: the executioner caspases, which initiate
the apoptotic cascade in response to extracellular signals
transduced by cell surface receptors such as TNFR1; and
the effector caspases, which are activated by the execu-
tioner caspases.
In a resting cell, caspases are present as proenzymes con-
taining prodomains. The prodomains must be cleaved off
to activate caspase activity. Cleavage of caspases is an
element of the two pathways of apoptosis operating in
mammalian cells: the ‘intrinsic’ pathway, which depends
on mitochondrial involvement; and the ‘extrinsic’ pathway,
which is independent of the mitochondria. The extrinsic
pathway is initiated by the binding of a ligand to a DR as
already described. In the intrinsic pathway, the mitochon-
dria in a stimulated cell make the critical decision whether
to initiate PCD [71]. In so doing, the mitochondria evalu-
ate the balance of apoptotic signals with other signals pro-
moting survival. If the net result favors the triggering of
apoptosis, cytochrome c is released from the mitochon-
dria at a level sufficient to initiate the activation of execu-
tioner caspases.
Specifically, cytochrome c in conjunction with dATP pro-
motes the association of procaspase-9 with apoptosis-
activating factor 1 (Apaf-1) [72]. This recruitment activates
caspase-9 through an unknown mechanism. Activated
caspase-9 in turn removes the prodomain of procaspase-
3, resulting in the activation of this critical effector
caspase (Fig. 2). Activated caspase-3 drives the apoptotic
process by degrading a panel of cellular proteins crucial
for cell survival
We have taken a genetic approach to dissecting apop-
totic pathways in various cell types. The evidence shows,
perhaps surprisingly, that not all elements are required in
all cell types or in response to all apoptotic agents.
Apoptosis-activating factor 1
Deficiency for Apaf-1 is embryonic lethal [73,74]. The
mutant embryos show dramatically reduced levels of
apoptosis in the brain, and hyperproliferation of neuronal
cells that leads to striking craniofacial deformities [73].
Analysis of various cell types lacking Apaf-1 confirmed the
vital role of this protein in the induction of apoptosis by a
range of stimuli. However, we were surprised to observe
that Fas-induced cell death of thymocytes and T cells was
normal in the absence of Apaf-1. This was the first clue
that, at least in some cell types, Fas-mediated apoptosis
occurs by mechanism that can bypass Apaf-1.
Caspase-3
Most caspase 3–/– mice die at or before birth [75,76]. The
few survivors are smaller than their littermates and have
visible masses in their heads. These masses are ectopic
protrusions of supernumerary cells that accumulate in
place of the pyknotic clusters usually derived from apopto-
sis during normal brain development [75,76]. Caspase-3
is thus crucial for normal embryonic development.
Deficiency for caspase-3 also dramatically reduces the
ability of many different cell types to undergo apoptosis in
different settings. For example, PCD of oncogenically
transformed MEF induced by a chemotherapeutic agent is
greatly compromised in the absence of caspase-3. Activa-
tion-induced cell death of peripheral T cells is also dramat-
ically reduced. However, while caspase-3 is necessary for
efficient apoptosis of embryonic stem cells following UV
irradiation, it is not required for PCD induced by γ-irradia-
tion [76]. In addition, the requirement for caspase-3 in
PCD induced by a given stimulus can be tissue specific.
For example, while TNF induces the apoptosis of caspase-
3–/– thymocytes, transformed caspase-3–/– MEFs are
resistant to this stimulus.
Finally, caspase-3 is required for certain events transpiring
during PCD but is not required for other events. In
response to certain stimuli, caspase-3–/– cells fail to
display DNA degradation or chromatin condensation but
still exhibit other physical signs characteristic of apoptosis
[76]. Thus, while caspase-3 is an important player in many
instances of PCD, it is dispensable in certain apoptotic
settings.
Caspase-9
Caspase-9 deficiency also results in embryonic lethality
due to defective brain development [77,78]. Analysis of
neuronal tissues of these mutant embryos again revealed
decreased apoptosis. Determination of the PCD of several
caspase-9–/– cell types showed that, like caspase-3,
caspase-9 is not required in all cell types for all apoptotic
events. Caspase-9 is necessary for the PCD of embryonic
stem cells and MEFs induced by UV irradiation or γ-irradia-
tion, and for PCD of thymocytes exposed to dexametha-
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sone or γ-irradiation. However, caspase-9–/– thymocytes
readily undergo apoptosis in response to UV irradiation or
engagement of Fas [78].
Future prospects and concluding remarks
Over the past decade, the understanding of the molecular
pathways leading to activation of apoptosis and cell sur-
vival has increased substantially. This knowledge is an
essential prerequisite to our contemplating the design of
therapeutics to combat diseases. It is now clear that in
addition to autoimmune diseases, this understanding will
help in the development of drugs that may have an impact
on the treatment of cancer and degenerative diseases.
Glossary of terms
Apaf-1 = apoptosis-activating factor 1; ASK-1 = apopto-
sis signal-regulating kinase 1; BAFF = B-lymphocyte acti-
vating factor; BAFF-R = BAFF receptor; BCMA = B-cell
maturation antigen; Bid = proapoptotic Bcl-2 family
member; Bim = proapoptotic Bcl-2 family member; DD =
death domain; DR = death receptor; FADD = Fas-associ-
ated death domain protein; c-FLIP = cellular homologue of
FLICE (caspase-8) inhibitory protein; GSK3 = glycogen
synthase kinase 3; IKK = IκB kinase; JNK = Jun kinase;
MAP3K = mitogen-activated protein 3 kinase; MEF =
mouse embryonic fibroblasts; MEKK = mitogen-activated
protein extracellular signal regulated kinase; NEMO =
NF-κB essential modulator protein; NIK = NF-κB inducing
kinase; OPGL = osteoproteregin ligand; PCD = pro-
grammed cell death; ζPKC = atypical protein kinase C;
RANK = receptor activator of NF-κB; RIP = receptor-inter-
acting protein; T2K = TRAF2-associated kinase; TACI =
transmembrane activator and calcium modulator and
cyclophilin ligand interactor; TANK = TRAF family member
associated NF-κB activator; TRADD = TNF receptor-asso-
ciated death domain protein; TRAF = TNF receptor-asso-
ciated factor; TNFR1 = TNF receptor-associated factor
type 1; TNFR2 = TNF receptor-associated factor type 2.
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treal, Quebec, Canada H3A 3C6), by the National Cancer Institute Of
Canada (10 Alcorn Avenue, Suite 200, Toronto, Ontario, Canada M4V
3B1), and by Canadian Institutes of Health Research (formerly the
Medical Research Council of Canada; 410 Laurier Avenue West, 9th
Floor, Address Locator 4209A, Ottawa, Ontario, Canada K1A 0W9).
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